Florian B Lagler

Head of Institute

Landeskrankenhaus Salzburg - Universitätsklinikum der Paracelsus Medizinischen Privatuniversität

Austria

Research Interests

Explore related searches

Professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Florian B Lagler is the Head of Institute at Paracelsus Medical University, Clinical Research Center Salzburg, Austria. His research focuses on the efficacy and safety of treatments for genetic disorders, including phenylketonuria and Pompe disease, as evident from his recent publications. He is actively involved in the development of innovative tools for personalized treatment trials and investigates integrated care coordination for patients with rare diseases.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (7)

Allan Lund

Professor of Paediatics

University of Copenhagen

DENMARK

View details

Brian W. Bigger

The University of Manchester

UNITED KINGDOM

View details

Walla Al-Hertani

Chief

Children's Hospital of Orange County

UNITED STATES

View details

Marianne Rohrbach

University of Zurich

SWITZERLAND

View details

Tobias Moser

AUSTRIA

View details

Markus Landolt

University of Zurich

SWITZERLAND

View details

Anne Smits

Prof. dr. at KU Leuven

KU Leuven

BELGIUM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Florian B Lagler

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The PompeQoL questionnaire: Development and validation of a new measure for children and adolescents with Pompe disease

Monitoring and integrated care coordination of patients with alpha-mannosidosis: A global Delphi consensus study

Living with Pompe disease: results from a qualitative interview study with children and adolescents and their caregivers

Efficacy and safety of sapropterin before and during pregnancy: Final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) maternal and Phenylketonuria Developmental Outcomes and Safety (PKUDOS) PKU-MOMs sub-registries

Long-term safety of sapropterin in paediatric and adult individuals with phenylalanine hydroxylase deficiency: Final results of the Kuvan® Adult Maternal Paediatric European Registry multinational observational study

An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis

RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565

An artificial intelligence-based approach for identifying rare disease patients using retrospective electronic health records applied for Pompe disease

Individual Treatment Trials—Do Experts Know and Use This Option to Improve the Treatability of Mucopolysaccharidosis?

Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

Collaborators (7)

Allan Lund

Brian W. Bigger

Walla Al-Hertani

Marianne Rohrbach

Tobias Moser

Markus Landolt

Anne Smits

Make your next move.